论文部分内容阅读
目的探讨康莱特联合化疗对乳腺癌患者T细胞亚群及肿瘤标志物的影响。方法选取2015年1月-2016年6月本院收治的乳腺癌患者110例作为研究对象,分为联合组55例和对照组55例,联合组与对照组均接受CAF化疗方案,联合组在化疗的基础上加用康莱特注射液,检测并比较2组治疗前后CD3~+、CD4~+、CD8~+、CD4~+/CD8~+水平以及癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)水平。结果治疗后联合组的CD3~+、CD4~+、CD4~+/CD8~+水平显著高于治疗前,且显著高于同期对照组;治疗后对照组的CD4~+水平显著低于治疗前,上述差异有统计学意义(P<0.05)。治疗后联合组的CEA、CA125、CA15-3水平低于对照组,2组的CEA、CA125、CA15-3水平均比治疗前降低,差异有统计学意义(P<0.05)。结论康莱特联合化疗可有效治疗乳腺癌,降低肿瘤标志物水平,显著改善乳腺癌患者T细胞亚群水平,提高患者免疫功能。
Objective To investigate the effect of Kanglaite combined with chemotherapy on T cell subsets and tumor markers in patients with breast cancer. Methods A total of 110 breast cancer patients treated in our hospital from January 2015 to June 2016 were selected and divided into 55 cases in combination group and 55 cases in control group. The combination group and control group received CAF chemotherapy regimen. On the basis of chemotherapy, Kanglaite injection was used to detect and compare the levels of CD3 ~ +, CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ + and carcinoembryonic antigen (CEA) (CA125), carbohydrate antigen 15-3 (CA15-3) levels. Results After treatment, the levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + in the combined group were significantly higher than those before treatment and significantly higher than those in the control group. CD4 ~ + levels in the control group were significantly lower than those before treatment , The difference was statistically significant (P <0.05). After treatment, the levels of CEA, CA125 and CA15-3 in the combined group were lower than those in the control group. The levels of CEA, CA125 and CA15-3 in the two groups were significantly lower than those before treatment (P <0.05). Conclusion Kanglaite combined chemotherapy can effectively treat breast cancer, reduce the level of tumor markers, significantly improve the level of T lymphocyte subsets in patients with breast cancer and improve the immune function of patients.